241 related articles for article (PubMed ID: 36345148)
1. Prognosis of resected invasive mucinous adenocarcinoma compared with the IASLC histologic grading system for invasive nonmucinous adenocarcinoma: Surgical database study in the TKIs era in Korea.
Woo W; Yang YH; Cha YJ; Moon DH; Shim HS; Cho A; Kim BJ; Kim HE; Park BJ; Lee JG; Kim DJ; Paik HC; Lee S; Lee CY
Thorac Cancer; 2022 Dec; 13(23):3310-3321. PubMed ID: 36345148
[TBL] [Abstract][Full Text] [Related]
2. Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas.
Lee HY; Cha MJ; Lee KS; Lee HY; Kwon OJ; Choi JY; Kim HK; Choi YS; Kim J; Shim YM
J Thorac Oncol; 2016 Jul; 11(7):1064-73. PubMed ID: 27016260
[TBL] [Abstract][Full Text] [Related]
3. Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma.
Woo W; Cha YJ; Kim BJ; Moon DH; Lee S
Clin Lung Cancer; 2022 Nov; 23(7):e435-e442. PubMed ID: 35945128
[TBL] [Abstract][Full Text] [Related]
4. Limited resection is comparable to lobectomy for tumor size ≤ 2 cm pulmonary invasive mucinous adenocarcinoma.
Lin W; Su H; Xie H; Xu L; Wang T; Wang L; Hu X; Zhao D; Zhu Y; Wang H; Jiang G; Xie D; Chen C;
World J Surg Oncol; 2024 Apr; 22(1):109. PubMed ID: 38664816
[TBL] [Abstract][Full Text] [Related]
5. High-grade tumor classified by new system is a prognostic predictor in resected lung adenocarcinoma.
Yoshida C; Yokomise H; Ibuki E; Go T; Haba R; Kadota K
Gen Thorac Cardiovasc Surg; 2022 May; 70(5):455-462. PubMed ID: 35050467
[TBL] [Abstract][Full Text] [Related]
6. Postoperative survival of pulmonary invasive mucinous adenocarcinoma versus non-mucinous invasive adenocarcinoma.
Cui D; Xie S; Liu Q
BMC Pulm Med; 2023 Jan; 23(1):9. PubMed ID: 36624430
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase fusion protein expression is associated with a favorable prognosis in resected invasive mucinous lung adenocarcinoma: A retrospective study from two Chinese tertiary hospitals.
Wang J; Wei P; Liu J; Su P; Xing A; Jing H; Hao J
J Cancer Res Ther; 2022 Apr; 18(2):445-451. PubMed ID: 35645113
[TBL] [Abstract][Full Text] [Related]
8. Clinical course of stage IV invasive mucinous adenocarcinoma of the lung.
Cha YJ; Kim HR; Lee HJ; Cho BC; Shim HS
Lung Cancer; 2016 Dec; 102():82-88. PubMed ID: 27987593
[TBL] [Abstract][Full Text] [Related]
9. The new IASLC grading system for invasive non-mucinous lung adenocarcinoma is a more useful indicator of patient survival compared with previous grading systems.
Yanagawa N; Sugai M; Shikanai S; Sugimoto R; Osakabe M; Uesugi N; Saito H; Maemondo M; Sugai T
J Surg Oncol; 2023 Jan; 127(1):174-182. PubMed ID: 36098331
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma.
Luo J; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Huang Q; Wang Y; Zheng J; Chen H
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1837-45. PubMed ID: 27342421
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective study.
Xu M; Hao Y; Zhou H; Shi Z; Si J; Song Z
Med Oncol; 2023 Jun; 40(7):198. PubMed ID: 37294384
[TBL] [Abstract][Full Text] [Related]
12. A Simplified Version of the IASLC Grading System for Invasive Pulmonary Adenocarcinomas With Improved Prognosis Discrimination.
Bossé Y; Gagné A; Althakfi WA; Orain M; Couture C; Trahan S; Pagé S; Joubert D; Fiset PO; Desmeules P; Joubert P
Am J Surg Pathol; 2023 Jun; 47(6):686-693. PubMed ID: 37032554
[TBL] [Abstract][Full Text] [Related]
13. [Construction of a Prognostic Prediction Model of Patients with Pathologic N0
in Resected Invasive Mucinous Adenocarcinoma of the Lung].
Wang Z; He J; Shen H; Chen X; Lin C; Yu H; Gao J; He X; Shen W
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):47-55. PubMed ID: 38296625
[TBL] [Abstract][Full Text] [Related]
14. EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system.
Nomura K; Aokage K; Kaminuma Y; Nakai T; Wakabayashi M; Ikeno T; Koike Y; Taki T; Miyoshi T; Tane K; Samejima J; Ishii G; Tsuboi M
Int J Clin Oncol; 2024 Mar; 29(3):248-257. PubMed ID: 38319510
[TBL] [Abstract][Full Text] [Related]
15. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
[TBL] [Abstract][Full Text] [Related]
16. Comparison of outcomes following lobectomy, segmentectomy, and wedge resection based on pathological subtyping in patients with pN0 invasive lung adenocarcinoma ≤1 cm.
Song W; Hou Y; Zhang J; Zhou Q
Cancer Med; 2022 Dec; 11(24):4784-4795. PubMed ID: 35570370
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of spread through air spaces in invasive mucinous lung adenocarcinoma after curative surgery.
Lee J; Cho S; Chung JH; Yoon SH; Shih BC; Jung W; Jeon JH; Kim K; Jheon S
Eur J Surg Oncol; 2024 Apr; 50(4):108053. PubMed ID: 38412587
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma.
Matsui T; Sakakura N; Koyama S; Nakanishi K; Sasaki E; Kato S; Hosoda W; Murakami Y; Kuroda H; Yatabe Y
Ann Thorac Surg; 2021 Oct; 112(4):1118-1126. PubMed ID: 33242433
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
Hong TH; Hwang S; Cho J; Choi YL; Han J; Lee G; Jeon YJ; Lee J; Park SY; Cho JH; Choi YS; Kim J; Shim YM; Kim HK
J Thorac Oncol; 2024 Mar; 19(3):425-433. PubMed ID: 37924973
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of mitosis and necrosis in non-mucinous lung adenocarcinomas and correlation with IASLC grading system.
Serın G; Savaş P; İşgör İŞ; Özdıl A; Mizrak A; Veral A; Nart D
Histol Histopathol; 2024 Jun; 39(6):703-714. PubMed ID: 37724635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
